StockData
Bio Essence Corp logo

Bio Essence Corp (BIOE) stock

BIOEOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/30
$0.42+0.03 (+7.72%)

Close on Oct 19, 2026Market cap $22.70MP/E 10.5Yield –

Bio Essence operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Bio Essence's operating income for the twelve months ending Sep 30, 2026 was $1.37M. For fiscal 2025 it was $900.01K. The highest annual figure on record is $900.01K in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$900.01K–
FY2024Dec 31, 2024-$459.44K–
FY2023Dec 31, 2023-$345.59K–
FY2022Dec 31, 2022-$511.14K–
FY2021Dec 31, 2021-$857.53K–
FY2020Dec 31, 2020-$832.57K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$159.13K-1216.4%
Q2 FY2026Jun 30, 2026$279.29K+356.2%
Q1 FY2026Mar 31, 2026$215.80K–
Q4 FY2025Dec 31, 2025$1.03M+26629.7%
Q3 FY2025Sep 30, 2025$14.25K–
Q2 FY2025Jun 30, 2025$61.22K–
Q1 FY2025Mar 31, 2025-$205.09K–
Q4 FY2024Dec 31, 2024$3.85K–
Q3 FY2024Sep 30, 2024-$146.45K–
Q2 FY2024Jun 30, 2024-$165.01K–
Q1 FY2024Mar 31, 2024-$151.83K–
Q4 FY2023Dec 31, 2023-$195.48K-406.6%
Q3 FY2023Sep 30, 2023-$82.64K–
Q2 FY2023Jun 30, 2023-$43.16K–
Q1 FY2023Mar 31, 2023-$24.31K–
Q4 FY2022Dec 31, 2022$63.76K–
Q3 FY2022Sep 30, 2022-$192.57K–
Q2 FY2022Jun 30, 2022-$155.90K–
Q1 FY2022Mar 31, 2022-$226.43K–
Q4 FY2021Dec 31, 2021-$198.77K–
Q3 FY2021Sep 30, 2021-$192.93K–
Q2 FY2021Jun 30, 2021-$261.30K–
Q1 FY2021Mar 31, 2021-$204.53K–
Q4 FY2020Dec 31, 2020-$328.82K–
Q3 FY2020Sep 30, 2020-$187.14K–
Q2 FY2020Jun 30, 2020-$196.26K–
Q1 FY2020Mar 31, 2020-$120.34K–

More Bio Essence figures

See a number that looks wrong?